Veterinary study shows Aroxxen-vet improves respiratory support and lowers anesthetic risks in hypoxic animals.
On a sample of animals (cats and dogs of different genders, of different ages with different diseases, a total of 30 individuals) in a state of hypoxia, a study was conducted on the correction of this condition with a medicinal product for veterinary use "Aroxxen-vet" (Aroxxen ® -vet), which is a mixture of oxygen, argon, xenon and nitrogen gases. The patient's exposure time in the box averaged 6 hours before surgical treatment for the underlying disease. During the study, various parameters of the respiratory and cardiovascular systems, body temperature, lactate levels, and arterial blood saturation were monitored. Measurements were performed before and after therapy with Aroxxen-vet gas. Based on the data obtained, it can be concluded that the use of mixtures of gases with a high content of inert gases (argon, xenon) and oxygen helps to stabilize the indicators of the functional state of the animal, slow down the progression of the underlying disease and, in some cases, improve the estimated indicators (lactate, BDD). Thus, the use of "Aroxxen-vet" (Aroxxen ® -vet) for 6 hours in animals in a state of hypoxia has a positive effect on the condition of the body in the preoperative period, which reduces anesthetic risks in the operational and postoperative periods. The use of this drug for veterinary use is a promising direction in the respiratory support of animals with a serious condition, increasing the effectiveness of pathogenetic therapy.
No takes yet. Share an insight, caveat, or question.
Ivanov et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: